Working with Springstone Financial, IntegraMed will be offering flexible installment loan financing for fertility procedures, supported by enhanced customer service, on-line capabilities, and consumer friendly terms.

Pamela Schumann, President of the Consumer Services Division of IntegraMed, commented, "This is a significant step in resolving both the challenges faced by our Consumer Services division when our principle lender exited the medical treatment financing businesses and our desire to offer an improved financing alternative. In the current economy, the ability to offer competitive and flexible patient financing has never been more important and represents a very clear competitive advantage for the IntegraMed Fertility Network.

"Selecting a consumer finance partner is a crucial decision for our Consumer Services division. We have previously worked very successfully with several of Springstone's principals and are confident that they understand the profile and needs of fertility patients. Our decision to partner with Springstone in bringing this one-of-kind program to market was largely based on their experience as well as their commitment to find creative ways to help patients receive the care they deserve. Springstone offers generous credit lines, highly competitive rates and a wide array of finance plans, all things we wanted to have built into our offering."

Based in Southborough, MA, Springstone is a leading provider of specialty medical financing. Its principals have over a decade of experience in helping thousands of customers significantly improve their lives by making medical procedures a possibility.

Mike Gilroy, President of Springstone, added, "We are very excited to partner with IntegraMed, the fertility industry leader. The idea they brought to the table was very compelling and allows Springstone to enter the fertility market through their network of centers performing about 25% of all IVF procedures in the US. We believe our partnership will support the continued growth of our respective businesses by providing better patient financing options and unparalleled customer service and support. Given the particularly strong credit performance they see in the fertility market, we are committed to help IntegraMed provide innovative and competitive financing options to its partners and affiliates."

About IntegraMed America, Inc.

IntegraMed America, Inc. manages highly specialized outpatient facilities in emerging, technology-based, niche medical markets and is the leading manager of fertility centers and vein clinics in the United States. IntegraMed supports its provider networks with clinical and business information systems, marketing and sales, facilities and operations management, finance and accounting, human resources, legal, risk management and quality assurance services. IntegraMed also offers treatment-financing programs for self-pay patients.

IntegraMed's fertility network is the nations largest fertility network, comprised of 36 contracted centers with over 100 locations in 31 states and the District of Columbia. Nearly one of every four IVF procedures in the U.S. is performed in an IntegraMed network fertility practice. The IntegraMed Vein Care network is the leading provider of varicose vein care services in the US, operating 34 centers in 13 states, principally in the Midwest and Southeast.

For more information about IntegraMed please visit:

www.integramed.com for investor background,

www.integramedfertility.com for fertility, or

www.veinclinics.com for vein care

SOURCE: IntegraMed America, Inc.

Investors: 
IntegraMed America, Inc. 
John W. Hlywak, Jr., EVP and CFO 
914-251-4143 
jhlywak@integramed.com 
or 
Media/Investors: 
Jaffoni & Collins Incorporated 
Norberto Aja, David Collins 
212-835-8500 
inmd@jcir.com

In a press release out on November 4, IntegraMed(R) Announces New Enhanced Consumer Finance Solution for Fertility Treatments

PURCHASE, N.Y., Nov 04, 2009 -- IntegraMed America, Inc. (NASDAQ: INMD), the nation's leading manager of specialty outpatient healthcare facilities in the emerging, technology-focused medical niches of fertility and vein care, today announced that it has partnered with Springstone Financial LLC to provide IntegraMed Fertility Network patients with improved financing options to fund Attain IVF Programs and certain other fertility treatments. Financing programs will be available to IntegraMed Fertility Network patients starting later this month.

About IntegraMed America, Inc.

IntegraMed America, Inc. manages highly specialized outpatient facilities in emerging, technology-based, niche medical markets and is the leading manager of fertility centers and vein clinics in the United States. IntegraMed supports its provider networks with clinical and business information systems, marketing and sales, facilities and operations management, finance and accounting, human resources, legal, risk management and quality assurance services. IntegraMed also offers treatment-financing programs for self-pay patients.

EDAP TMS SA (Nasdaq:EDAP) trading at $3.19 per share on trading volume of 44,725 shares.

In a press release out on November 4, EDAP Announces Webcast and Conference Call of Third Quarter 2009 Results

LYON, France, Nov 4, 2009 -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today details relating to its third quarter 2009 earnings announcement, which will take place on Tuesday, November 17, 2009, before the opening of the market.

About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the company, please visit http://www.edap-tms.com,http://www.hifu-planet.com and http://www.pcaresearch.com.

ICOP Digital, Inc. (Nasdaq:ICOP) trading at $0.546 on a volume of 90,938 shares

In a press release out on November 4, ICOP to Host Teleconference on November 11, 2009

Management to Review Third Quarter 2009 Financial Results

LENEXA, Kan., Nov 4, 2009 -- ICOP Digital, Inc. (Nasdaq:ICOP), an industry-leading company engaged in advancing digital surveillance technology solutions, announced today that the Company will host a teleconference on November 11, 2009, to review its third quarter 2009 financial information and results. The Company plans to file its 10-Q on Friday November 13, 2009. ICOP is a leading provider of advanced digital video surveillance and management solutions.

About ICOP Digital, Inc.

ICOP Digital, Inc. (Nasdaq:ICOP) is a leading provider of mobile video solutions for Law Enforcement, Fire, EMS, Military, and Transportation markets, worldwide. ICOP solutions help the public and private sectors mitigate risks, reduce losses, and improve security through the live streaming, capture and secure management of high quality video and audio. www.ICOP.com

Celadon Group Inc. (NASDAQ: CLDN) trading at $9.51 on a volume of 33,055 shares

In a press release out on November 4, Celadon Group Announces Dates for Earnings Release and Conference Call

INDIANAPOLIS, Nov 04, 2009 -- Celadon Group Inc. (NASDAQ: CLDN) will release its fiscal 2010 second quarter results on Monday, January 25 after the close of the market. A conference call to discuss the quarter will be held on Tuesday, January 26 at 10:00 a.m. ET.

Celadon Group Inc. (www.celadongroup.com), through its subsidiaries, primarily provides long-haul, full-truckload freight service across the United States, Canada and Mexico. The company also owns Celadon Logistics Services, which provides freight brokerage; Celadon Dedicated Services, which provides supply chain management solutions, such as warehousing and dedicated fleet services; and TruckersB2B (www.truckersb2b.com) which provides cost savings to member fleets.

Xtremepicks.com profiles early stage microcap and growth stocks that provide innovative products or services resulting in potentially "hyper-growth" opportunities. Often, these companies have yet to be recognized by Wall Street and the undiscovered nature of Xtremepicks.com's profile companies provide our members the opportunity to learn about these companies at their development stage, and more importantly before they possibly "turn the corner" and get exposed to a much larger investing audience.

Xtremepicks.com (www.Xtremepicks.com) has prepared all material herein based upon information believed to be reliable. The information contained herein is not guaranteed by Xtremepicks.com to be accurate, and should not be considered to be all-inclusive. Xtremepicks.com is a leading information resource for evaluating investment opportunities in small and microcap stocks. We focus on a limited number of companies in order to provide comprehensive coverage, including unique investment related features not available anywhere else on the Internet. To feature a company or to get more information, please visit us at www.Xtremepicks.com or email us at info@Xtremepicks.com Xtremepicks.coms affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value. Xtremepicks.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

To view full disclaimers, go to http://www.Xtremepicks.com/disclaimer.htm

CONTACT: Xtremepicks.com email: Info@xtremepicks.com WWW: http://www.Xtremepicks.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Live Webcast and Replay:  Available at http://www.integramed.com
                          (Investor Relations web page) or at www.earnings.com
                          and archived for 30 days.
Dial-in Numbers:          (866) 395-2657 or (706) 902-0717 (International)
Phone Replay:             (800) 642-1687 or (706) 645-9291; #37103590, through Nov. 6

About IntegraMed America, Inc.

IntegraMed America, Inc. manages highly specialized outpatient facilities in emerging, technology-based, niche medical markets and is the leading manager of fertility centers and vein clinics in the United States. IntegraMed supports its provider networks with clinical and business information systems, marketing and sales, facilities and operations management, finance and accounting, human resources, legal, risk management and quality assurance services. IntegraMed also offers treatment-financing programs for self-pay patients.

IntegraMed's fertility network is the nations largest fertility network, comprised of 36 contracted centers with over 100 locations in 31 states and the District of Columbia. Nearly one of every four IVF procedures in the U.S. is performed in an IntegraMed network fertility practice. The IntegraMed Vein Care network is the leading provider of varicose vein care services in the US, operating 34 centers in 13 states, principally in the Midwest and Southeast.

For more information about IntegraMed please visit: www.integramed.com for investor, background, www.integramedfertility.com for fertility, or www.veinclinics.com for vein care.

SOURCE: IntegraMed America, Inc.

Jaffoni & Collins Incorporated 
David Collins, Norberto Aja 
212-835-8500 
inmd@jcir.com